Created at	Source	Raw Value	Validated value
Nov. 26, 2021, 10:30 p.m.	oms	1.To evaluate the reactogenicity and safety of BBV154 (Adenoviral vectored based SARS-CoV-2 virus) vaccine administered via the intranasal route. <br/ > <br/ > <br/ >Timepoint: Baseline; Day 28 [Time Frame: within 2 hours post each vaccination] <br/ >[Time Frame: 7 days]. <br/ >The occurrence of serious adverse events (SAEs) [Time Frame: throughout the study duration]. <br/ >The occurrence of any unsolicited adverse events up to day 35 from 1st dose vaccination. [Time Frame: up to day 35 from 1st dose vaccination].	1.To evaluate the reactogenicity and safety of BBV154 (Adenoviral vectored based SARS-CoV-2 virus) vaccine administered via the intranasal route. <br/ > <br/ > <br/ >Timepoint: Baseline; Day 28 [Time Frame: within 2 hours post each vaccination] <br/ >[Time Frame: 7 days]. <br/ >The occurrence of serious adverse events (SAEs) [Time Frame: throughout the study duration]. <br/ >The occurrence of any unsolicited adverse events up to day 35 from 1st dose vaccination. [Time Frame: up to day 35 from 1st dose vaccination].
Nov. 13, 2021, 5:33 p.m.	oms	N/A	N/A
Feb. 27, 2021, 12:45 a.m.	oms	1.To evaluate the reactogenicity and safety of BBV154 (Adenoviral vectored based SARS-CoV-2 virus) vaccine administered via the intranasal route. <br/ > <br/ > <br/ >Timepoint: Baseline; Day 28 [Time Frame: within 2 hours post each vaccination] <br/ >[Time Frame: 7 days]. <br/ >The occurrence of serious adverse events (SAEs) [Time Frame: throughout the study duration]. <br/ >The occurrence of any unsolicited adverse events up to day 35 from 1st dose vaccination. [Time Frame: up to day 35 from 1st dose vaccination].	1.To evaluate the reactogenicity and safety of BBV154 (Adenoviral vectored based SARS-CoV-2 virus) vaccine administered via the intranasal route. <br/ > <br/ > <br/ >Timepoint: Baseline; Day 28 [Time Frame: within 2 hours post each vaccination] <br/ >[Time Frame: 7 days]. <br/ >The occurrence of serious adverse events (SAEs) [Time Frame: throughout the study duration]. <br/ >The occurrence of any unsolicited adverse events up to day 35 from 1st dose vaccination. [Time Frame: up to day 35 from 1st dose vaccination].